Douglas Goodin. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedClinical Trials as TopicDecision MakingDrug IndustryHumansLeukoencephalopathy, Progressive Multifocal/chemically inducedMarketing of Health ServicesMultiple Sclerosis/drug therapyNatalizumab
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedNatalizumab
Year: 2006 PMID: 16632301 DOI: 10.1016/S1474-4422(06)70419-7
Source DB: PubMed Journal: Lancet Neurol ISSN: 1474-4422 Impact factor: 44.182